share_log

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Benzinga Real-time News ·  Aug 5, 2022 11:36

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus

FDA Signs Off Marker Therapeutics Cell Therapy Study In Lymphoma Setting

The FDA clearedMarker Therapeutics Inc's(NASDAQ:MRKR) Investigational New Drug (IND) application for MT-601 for relapsed/refractory non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment.

MT-601 is a multi-tumor-associated antigen (multiTAA)-specific T cell product targeting six antigens.

In addition, the FDA has cleared Marker to initiate its study at a dose level of 200 million cells per infusion versus...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment